U.S. authorities allege that two top officials of CANARX, a Canadian company, ran a long-running scheme to illegally import prescription drugs into the United States. According to court records filed Tuesday, John Thomas Howard, the company's treasurer and a director, was arrested Sunday on smuggling and conspiracy charges. His brother, Bob Howard, the president and a director, is also wanted, according to an affidavit from FDA special agent Dustin Dobbs. Those are allegations, not convictions, and no plea has been filed. Still, the pattern they describe deserves more scrutiny than a company's assurances.
CANARX said it was the first international prescription provider for the U.S. and the safest such program in the industry. The affidavit tells a different story, stating there is probable cause to believe the company illegally imported or caused the illegal importation of prescription drugs. The complaint covers the period from Feb. 22, 2017, through April 15, 2026. The FDA had already seized medication from CANARX in 2023 that it said was potentially misbranded and counterfeit, and a 2019 warning letter objected to substituting FDA-approved drugs with unapproved ones. The company's general counsel, Joseph Morris, said the Howards deny the charges and expect to be vindicated. That denial deserves a fair hearing in court, but a company that has been warned repeatedly cannot simply rely on the claim that its medicines come from highly regulated countries.
The broader problem is the business model itself. Alternative funding programs have spread through employers and healthcare systems by promising cheaper specialty drugs, and in some cases workers are required to use them. The FDA spokesperson's statement that, in most circumstances, a person cannot import prescription drugs as substitutes for FDA-approved drugs makes the legal line clear. Patients who depend on these shipments are the ones who bear the risk if a medication is misbranded, counterfeit, or mishandled, and they often have little way to know the supply chain behind their pills. Gilead Sciences' separate lawsuit over Biktarvy, an HIV medication, shows that the harm is not hypothetical.
Employers and benefits managers should stop treating an AFP as a cost-saving shortcut without verifying where the drugs come from and whether they are lawful. Regulators should act on the record already in front of them rather than waiting for a series of warning letters to accumulate. Congress and the FDA should also make clear what importation is permitted for individual use, so that companies cannot build entire models on an ambiguous exception. Lower drug prices are a legitimate goal, but they cannot be pursued by moving medicines through channels the pharmaceutical makers never authorized.